“The European Neuromodulation market is estimated to grow at a CAGR of 13.6% from 2014 to 2019. In 2014, Germany commanded a larger share of around 27.2% of the European neuromodulation market, followed by France. Increasing incidences of peripheral nerve injuries and neurological disorders, technological developments in nerve repair, and favorable reimbursement policies are expected to drive the market growth in this region. However, lacks of surgeons and patient awareness have an adverse effect on the neuromodulation market.
In this report, the European neuromodulation market is broadly classified on the basis of procedure type and modality. The procedure segment is classified into internal stimulation and external stimulation. Based on modalities, the neuromodulation market is categorized into spinal cord stimulation, deep brain stimulation, vagus, nerve stimulation, sacral nerve stimulation, gastric electric stimulation, transcutaneous electrical nerve stimulation (TENS), and transcranial magnetic stimulation (TMS).
Geographically, the market is divided into six countries, namely Germany, France, the U.K., Italy, Spain, and the RoE. Germany commanded the largest share of 27.2% of the European neuromodulation market in 2014, followed by France. The market in Germany is estimated to grow at a CAGR of 13.9% during the forecast period.
Neuromodulation is one of the largest and fastest-growing segments of the global medical devices market. The number of novel neuromodulation devices approved by the FDA grew 35% in 2007, promising new neuromodulation therapies for diverse disorders such as migraine, obesity, obsessive compulsive disorder, and depression. Advances in neuromodulation therapies are multi-disciplinary, requiring the close collaboration of neuroscientists, engineers, and clinicians to reach fruition.
The report has profiled the leading players in this market along with their developments (new product launches and partnerships, agreements, collaborations, and joint ventures) over the past few years and strategies adopted by them to sustain and strengthen their position in the European neuromodulation market. Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Depuy Synthes (Johnson & Johnson) (U.S.), and St. Jude Medical Inc. (U.S.) are some of the key players engaged in this market.
Reasons to Buy the Report:
From an insight perspective, this research report has focused on various levels of analysis—industry analysis (industry trends, and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, usage patterns, emerging- and high-growth segments of the European Neuromodulation market, high-growth regions and countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market, share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.
The report provides insights on the following pointers:
• Product Analysis and Development: Detailed insights on upcoming technologies, research and development activities, and new product launches in the European neuromodulation market. Usage pattern/ penetration rate (in-depth trend analysis) of products (segment-wise) and purchasing data. Comprehensive coverage of product approvals, patent analysis, pipeline products, and product recalls.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for neuromodulation across geographies and exploits new distribution channels, new clientele base, and different pricing policies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments decisions in the neuromodulation market. Detailed description regarding the related and unrelated diversification pertaining to this market.
• Epidemiology Data: The incidences and patient pool of Alzheimer’s, Parkinson’s, epilepsy and stroke, and disease progression.
• Competitive Assessment: In-depth assessment of market shares, company share analysis of the key players forecast till 2019. Develop business strategies and manufacturing capabilities of leading players enhance the bottom line of the companies in the neuromodulation market.
• Product/Brand Perception Analysis: Comprehensive study of customers perception and behavior through our inbuilt social connect tool (digital marketing language) checking the virality and tonality of blogs
”
“TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET SEGMENTATION & COVERAGE 12
1.3 STAKEHOLDERS 12
2 RESEARCH METHODOLOGY 13
2.1 INTEGRATED ECOSYSTEM OF NEUROMODULATION MARKET 14
2.2 ARRIVING AT THE EUROPE NEUROMODULATION MARKET SIZE 15
2.2.1 TOP-DOWN APPROACH 15
2.2.2 BOTTOM-UP APPROACH 17
2.2.3 MACROINDICATOR-BASED APPROACH 18
2.3 ASSUMPTIONS 19
3 EXECUTIVE SUMMARY 20
4 MARKET OVERVIEW 22
4.1 INTRODUCTION 22
4.2 NEUROMODULATION MARKET: COMPARISON WITH PARENT MARKET (NERVE REPAIR & REGENERATION), 2013–2019 (USD MN) 23
4.3 MARKET DRIVERS AND INHIBITORS 24
4.4 KEY MARKET DYNAMICS 25
5 EUROPE NEUROMODULATION MARKET, BY PROCEDURE 27
5.1 INTRODUCTION 28
5.2 EUROPE INTERNAL STIMULATION 29
5.2.1 EUROPE NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,
BY GEOGRAPHY 30
5.2.2 EUROPE NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,
BY GEOGRAPHY 31
5.2.3 EUROPE NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,
BY GEOGRAPHY 32
5.2.4 EUROPE NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,
BY GEOGRAPHY 33
5.2.5 EUROPE NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY GEOGRAPHY 34
5.3 EUROPE EXTERNAL STIMULATION 35
5.3.1 EUROPE NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GEOGRAPHY 36
5.3.2 EUROPE NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY GEOGRAPHY 37
6 EUROPE NEUROMODULATION MARKET, BY GEOGRAPHY 39
6.1 INTRODUCTION 40
6.2 GERMANY NEUROMODULATION MARKET, BY PROCEDURE 41
6.2.1 GERMANY NEUROMODULATION MARKET, BY INTERNAL STIMULATION 43
6.2.2 GERMANY NEUROMODULATION MARKET, BY EXTERNAL STIMULATION 44
6.3 FRANCE NEUROMODULATION MARKET, BY PROCEDURE 46
6.3.1 FRANCE NEUROMODULATION MARKET, BY INTERNAL STIMULATION 47
6.3.2 FRANCE NEUROMODULATION MARKET, BY EXTERNAL STIMULATION 49
6.4 U.K. NEUROMODULATION MARKET, BY PROCEDURE 50
6.4.1 U.K. NEUROMODULATION MARKET, BY INTERNAL STIMULATION 52
6.4.2 U.K. NEUROMODULATION MARKET, BY EXTERNAL STIMULATION 53
6.5 ITALY NEUROMODULATION MARKET, BY PROCEDURE 55
6.5.1 ITALY NEUROMODULATION MARKET, BY INTERNAL STIMULATION 56
6.5.2 ITALY NEUROMODULATION MARKET, BY EXTERNAL STIMULATION 58
6.6 SPAIN NEUROMODULATION MARKET, BY PROCEDURE 59
6.6.1 SPAIN NEUROMODULATION MARKET, BY INTERNAL STIMULATION 61
6.6.2 SPAIN NEUROMODULATION MARKET, BY EXTERNAL STIMULATION 62
7 EUROPE NEUROMODULATION MARKET: COMPETITIVE LANDSCAPE 64
7.1 EUROPE NEUROMODULATION MARKET: MARKET SHARE ANALYSIS 64
7.2 COMPANY PRESENCE IN EUROPEAN NEUROMODULATION MARKET, BY TYPE 65
7.1 MERGERS & ACQUISITIONS 66
7.2 EXPANSIONS 67
7.3 INVESTMENTS 67
7.4 JOINT VENTURES 67
7.5 PRODUCT APPROVALS 68
7.6 NEW PRODUCT DEVELOPEMENT 70
8 EUROPE NEUROMODULATION MARKET: BY COMPANY 71
(Overview, Financials, Products & Services, Strategy, and Developments)*
8.1 BOSTON SCIENTIFIC CORPORATION 71
8.2 CERBOMED GMBH 75
8.3 CYBERONICS, INC. 77
8.4 DEPUY SYNTHES 79
8.5 MEDTRONIC, INC. 82
8.6 ST. JUDE MEDICAL 85
8.7 UROPLASTY, INC. 88
8.8 ANM ADAPTIVE NEUROMODULATION GMBH 90
8.9 THE MAGSTIM COMPANY LIMITED 91
8.10 BIOCONTROL MEDICAL, LTD. 92
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted company
9 APPENDIX 93
9.1 CUSTOMIZATION OPTIONS 93
9.1.1 PRODUCT ANALYSIS 93
9.1.2 EPIDEMIOLOGY DATA 93
9.1.3 PROCEDURE VOLUME DATA 93
9.1.4 SURGEON/PHYSICIAN PERCEPTION ANALYSIS 93
9.1.5 BRAND/PRODUCT PERCEPTION MATRIX 94
9.1.6 PRICING TRENDS 94
9.1.7 COMPETITIVE INTELLIGENCE 94
9.2 RELATED REPORTS 95
9.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 96
9.3.1 RT SNAPSHOTS 97
“
“LIST OF TABLES
TABLE 1 EUROPE NEUROMOLDULATION MARKET: MACROINDICATORS,BY COUNTRY,
2014 (USD MN) 18
TABLE 2 EUROPE NEUROMODULATION MARKET: COMPARISON WITH PARENT MARKET (NERVE REPAIR & REGENERATION), 2013 – 2019 (USD MILLION) 23
TABLE 3 EUROPE NEUROMODULATION MARKET: DRIVERS AND INHIBITORS 24
TABLE 4 EUROPE: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 25
TABLE 5 EUROPE: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 26
TABLE 6 EUROPE: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 26
TABLE 7 EUROPE: NEUROMODULATION MARKET, BY GEOGRAPHY, 2013 – 2019 (USD MN) 26
TABLE 8 EUROPE: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 28
TABLE 9 EUROPE: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 30
TABLE 10 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 31
TABLE 11 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 32
TABLE 12 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 33
TABLE 13 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION
BY GEOGRAPHY, 2013 – 2019 (USD MN) 34
TABLE 14 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 35
TABLE 15 EUROPE: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 36
TABLE 16 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GEOGRAPHY, 2013 – 2019 (USD MN) 37
TABLE 17 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY GEOGRAPHY, 2013 – 2019 (USD MN) 38
TABLE 18 EUROPE: NEUROMODULATION MARKET, BY GEOGRAPHY, 2013 – 2019 (USD MN) 41
TABLE 19 GERMANY: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 42
TABLE 20 GERMANY: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 43
TABLE 21 GERMANY: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 45
TABLE 22 FRANCE: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 46
TABLE 23 FRANCE: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 48
TABLE 24 FRANCE: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 49
TABLE 25 U.K.: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 51
TABLE 26 U.K.: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 52
TABLE 27 U.K.: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 54
TABLE 28 ITALY: NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 55
TABLE 29 ITALY: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013 – 2019 (USD MN) 57
TABLE 30 ITALY: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 58
TABLE 31 SPAIN NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 60
TABLE 32 SPAIN: NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2013-2019 (USD MN) 61
TABLE 33 SPAIN: NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2013 – 2019 (USD MN) 63
TABLE 34 EUROPE NEUROMODULATION MARKET: MARKET SHARE ANALYSIS, 2013 (%) 64
TABLE 35 EUROPE NEUROMODULATION MARKET: MERGERS & ACQUISITIONS 66
TABLE 36 EUROPE NEUROMODULATION MARKET: EXPANSIONS 67
TABLE 37 EUROPE NEUROMODULATION MARKET: INVESTMENTS 67
TABLE 38 EUROPE NEUROMODULATION MARKET: AGREEMENT 67
TABLE 39 EUROPE NEUROMODULATION MARKET: PRODUCT APPROVALS 68
TABLE 40 EUROPE NEUROMODULATION MARKET: NEW PRODUCT DEVELOPMENT 70
TABLE 41 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS, BY SEGMENT,
2009 – 2013 (USD MN) 72
TABLE 42 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS, BY REGION,
2009 – 2012 (USD MN) 72
TABLE 43 CYBERONICS, INC.: KEY FINANCIALS, 2009 – 2013 (USD MN) 77
TABLE 44 JOHNSON & JOHNSON, INC.: KEY FINANCIALS, BY SEGMENT, 2009 – 2013 (USD MN) 80
TABLE 45 JOHNSON & JOHNSON, INC.: KEY FINANCIALS, BY REGION, 2009 – 2013 (USD MN) 80
TABLE 46 MEDTRONIC, INC.: KEY FINANCIALS, BY SEGMENT, 2009 – 2013 (USD MN) 83
TABLE 47 MEDTRONIC, INC.: KEY FINANCIALS, BY REGION, 2009 – 2013 (USD MN) 83
TABLE 48 ST. JUDE MEDICAL: KEY FINANCIALS, BY SEGMENT, 2011 – 2013 (USD MN) 86
TABLE 49 ST. JUDE MEDICAL: KEY FINANCIALS, BY REGION, 2009 – 2013 (USD MN) 86
TABLE 50 UROPLASTY, INC.: KEY FINANCIALS, BY REGION, 2011 – 2013 (USD MN) 88
“
“LIST OF FIGURES
FIGURE 1 EUROPEAN NEUROMODULATION MARKET: SEGMENTATION & COVERAGE 12
FIGURE 2 NEUROMODULATION MARKET: INTEGRATED ECOSYSTEM 14
FIGURE 3 RESEARCH METHODOLOGY 15
FIGURE 4 TOP-DOWN APPROACH 16
FIGURE 5 BOTTOM-UP APPROACH 17
FIGURE 6 MACROINDICATOR-BASED APPROACH 18
FIGURE 7 EUROPE NEUROMODULATION MARKET SNAPSHOT (TOP MARKETS), 2014 21
FIGURE 8 EUROPE NEUROMODULATION PROCEDURES MARKET, BY GEOGRAPHY,
2014 (USD MN) 25
FIGURE 9 EUROPE NEUROMODULATION MARKET, BY PROCEDURE, 2014 VS 2019 (USD MN) 28
FIGURE 10 EUROPE NEUROMODULATION MARKET, BY PROCEDURE, 2013 – 2019 (USD MN) 29
FIGURE 11 EUROPE NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014 VS. 2019 (USD MN) 29
FIGURE 12 EUROPE NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,
BY GEOGRAPHY, 2014 – 2019 (USD MN) 30
FIGURE 13 EUROPE NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,
BY GEOGRAPHY, 2014 – 2019 (USD MN) 31
FIGURE 14 EUROPE NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 32
FIGURE 15 EUROPE NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 33
FIGURE 16 EUROPE NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,
BY GEOGRAPHY, 2013 – 2019 (USD MN) 34
FIGURE 17 EUROPE NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014 VS. 2019 (USD MN) 35
FIGURE 18 EUROPE NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GEOGRAPHY, 2014 – 2019 (USD MN) 36
FIGURE 19 EUROPEAN NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY GEOGRAPHY, 2013 – 2019 (USD MN) 37
FIGURE 20 EUROPE NEUROMODULATION MARKET: GROWTH ANALYSIS, BY GEOGRAPHY,
2014 (USD MILLION) 40
FIGURE 21 GERMANY NEUROMODULATION MARKET, BY PROCEDURE, 2014 – 2019 (USD MN) 41
FIGURE 22 GERMANY NEUROMODULATION MARKET: PROCEDURE SNAPSHOT 42
FIGURE 23 GERMANY NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014 – 2019 (USD MN) 43
FIGURE 24 GERMANY INTERNAL NEUROMODULATION MARKET: SNAPSHOT 44
FIGURE 25 GERMANY NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014 – 2019 (USD MN) 44
FIGURE 26 GERMANY EXTERNAL NEUROMODULATION MARKET: SNAPSHOT 45
FIGURE 27 FRANCE NEUROMODULATION MARKET, BY PROCEDURE, 2014 – 2019 (USD MN) 46
FIGURE 28 FRANCE NEUROMODULATION MARKET: PROCEDURE SNAPSHOT 47
FIGURE 29 FRANCE NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014–2019 (USD MN) 47
FIGURE 30 FRANCE INTERNAL NEUROMODULATION MARKET: SNAPSHOT 48
FIGURE 31 FRANCE NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014 – 2019 (USD MN) 49
FIGURE 32 FRANCE EXTERNAL NEUROMODULATION MARKET: SNAPSHOT 50
FIGURE 33 U.K. NEUROMODULATION MARKET, BY PROCEDURE, 2014 – 2019 (USD MN) 50
FIGURE 34 U.K. NEUROMODULATION MARKET: PROCEDURE SNAPSHOT 51
FIGURE 35 U.K. NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014 – 2019 (USD MN) 52
FIGURE 36 U.K. INTERNAL NEUROMODULATION MARKET: SNAPSHOT 53
FIGURE 37 U.K. NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014–2019 (USD MN) 53
FIGURE 38 U.K. EXTERNAL NEUROMODULATION MARKET: SNAPSHOT 54
FIGURE 39 ITALY NEUROMODULATION MARKET, BY PROCEDURE, 2014 – 2019 (USD MN) 55
FIGURE 40 ITALY NEUROMODULATION MARKET: PROCEDURE SNAPSHOT 56
FIGURE 41 ITALY NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014 – 2019 (USD MN) 56
FIGURE 42 ITALY INTERNAL NEUROMODULATION MARKET: SNAPSHOT 57
FIGURE 43 ITALY NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014 – 2019 (USD MN) 58
FIGURE 44 ITALY EXTERNAL NEUROMODULATION MARKET: SNAPSHOT 59
FIGURE 45 SPAIN NEUROMODULATION MARKET, BY PROCEDURE, 2014 – 2019 (USD MN) 59
FIGURE 46 SPAIN NEUROMODULATION MARKET: PROCEDURE SNAPSHOT 60
FIGURE 47 SPAIN NEUROMODULATION MARKET, BY INTERNAL STIMULATION,
2014 – 2019 (USD MN) 61
FIGURE 48 SPAIN INTERNAL NEUROMODULATION MARKET: SNAPSHOT 62
FIGURE 49 SPAIN NEUROMODULATION MARKET, BY EXTERNAL STIMULATION,
2014 – 2019 (USD MN) 62
FIGURE 50 SPAIN EXTERNAL NEUROMODULATION MARKET: SNAPSHOT 63
FIGURE 51 EUROPE NEUROMODULATION MARKET SHARE ANALYSIS, 2013 (%) 64
FIGURE 52 EUROPE NEUROMODULATION MARKET: COMPANY PRODUCT COVERAGE,
BY TYPE, 2013 65
FIGURE 53 BOSTON SCIENTIFIC CORPORATION: BUSINESS REVENUE MIX, 2013 71
FIGURE 54 DEPUY SYNTHES: REVENUE MIX, 2013 79
FIGURE 55 MEDTRONIC, INC.: REVENUE MIX, 2013 82
FIGURE 56 ST. JUDE MEDICAL.: REVENUE MIX, 2013 85
“
